NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

The British magic circle law firm Freshfields revealed it was serious about a US expansion when it poached star M&A lawyer ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Procurement Magazine takes a look back at the biggest news from across the industry over the last seven days, including SAP, ...

Lars Fruergaard Jørgensen. "The acquisition will enable us to reach significantly more people living with serious chronic diseases," he added. Novo Nordisk has previously indicated that the ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

The U.S.-based network infrastructure provider has spent years working to lower its debt in the wake of sizable acquisitions and economic challenges during the pandemic that stunted its growth. The ...

David Bellew, senior director, client services at Yardi®, was elected to the Argentum Board of Directors and took a seat at the May 20 board meeting. Argentum is the leading national trade association ...

For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.

Under a mutual agreement with the board of directors, longtime Novo Nordisk CEO Lars Fruergaard Jørgensen—who recently ...

Investment research Market and company reports Stock market data Share Exchange ...